News|Articles|June 2, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-06-07-2016
  • Volume 11
  • Issue 6

Novasep Starts Kilogram-Scale Batch Production at US Facility

Production of kilogram-scale batches of synthetic molecules for early-stage development are now available to US customers.

Novasep has finalized the set-up of its new synthesis laboratory and kilogram-scale laboratory at its Pennsylvania, US facility. Production of kilogram-scale batches of synthetic molecules for biological testing and preclinical trials has begun.


“Drug developers in the US are responding positively to our extended CMO services that support their early stage programs," said Andrew Brennan, general manager at Novasep’s US operations, in a press release.

“The proximity to our US experts will help to secure and speed up our customers’ projects. And beyond the technical expertise of our team, the trusted partnerships that Novasep is building with US companies will promote future development and commercial supply agreements to keep up with the fast growing US pharmaceutical market,” said Thierry Van Nieuwenhove, Synthesis BU president.

The facility in Boothwyn, PA is equipped with jacketed reactors ranging from 100 mL to 50 L in size and with a 3 5L filter dryer for isolation of kilogram quantities of compound. The laboratory extension has equipment for standard and cryogenic chemistry. For purification services, the laboratory provides North American customers with Novasep’s preparative chromatography technologies and has analytical tools for process research and development, including a calorimetric reactor for preliminary process safety testing.
 

Source: Novasep


Related to this article

Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.